Journal
ANNALS OF ONCOLOGY
Volume 11, Issue 4, Pages 435-440Publisher
ELSEVIER
DOI: 10.1023/A:1008336931378
Keywords
cisplatin; MTA; non-small-cell lung cancer (NSCLC); phase II
Categories
Ask authors/readers for more resources
Background: To evaluate the activity of MTA plus cisplatin in chemotherapy-naive patients with non-small cell lung cancer (NSCLC). Patients and methods: Thirty-six chemotherapy-naive patients with NSCLC received 500 mg/m(2) MTA plus 75 mg/m(2) cisplatin every 21 days, with 4 mg dexamethasone orally twice daily on the day before, of, and after MTA administration. Results: Median age was 58 years. WHO performance status was 0-2. Eighteen patients each had stage IIIB and IV disease. Seventeen patients each had squamous-cell and adenocarcinoma; two had undifferentiated disease. Fourteen patients (39%; 95% confidence interval: 23%-57%) showed partial response; seventeen (47%) had stable disease. Median survival was 10.9 months. Twenty-one patients (59%) experienced grade 3 or 4 granulocytopenia without fever or infection. Five (14%) and six (17%) patients experienced grade 3 anemia and grade 3 or 4 thrombocytopenia, respectively. Nonhematological toxicities included grade 3 nausea in two patients (6%), and grade 3 and 4 diarrhea in one patient (3%) each. One patient each experienced grade 4 ALT and grade 3 bilirubin and AST elevations. Conclusions: MTA plus cisplatin is well tolerated and active against NSCLC. Further studies of this combination are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available